Navigation Links
Pevion's Therapeutic Candida Vaccine Generates Functional B Cell Memory in all Vaccinees
Date:1/17/2012

BERN, Switzerland, January 17, 2012 /PRNewswire/ --

Pevion Biotech AG today announced further data from the ongoing clinical study of its therapeutic Candida vaccine PEV7, demonstrating the generation of specific and functional B cell memory in 100% of vaccinees. Furthermore, the results again confirm the capability of Pevion's second generation virosomal vaccine platform to induce strong and long-lasting immunity in humans against otherwise weak antigens .

Following the previously announced positive safety and immunogenicity results of PEV7, the Company further investigated the vaccine-induced generation of B cell memory. To this end, half of the group of volunteers vaccinated with the intramuscular low dose of PEV7 received a single booster immunization fourteen months after the primary vaccination course. All vaccinees showed a rapid, specific response either in serum or in cervicovaginal secretion or in both, after antibody titers had come down to baseline six months prior to the boost in this low-dose group.

"Based on analyses of antibody functionality, as monitored by competitive target inhibition, and antigen specific reactivity, we have evidence for an affinity maturation of these antibodies," explained Christian Moser, Head of Research at Pevion. "We are very satisfied to see such an excellent induction of memory by the PEV7 vaccine even at low dose, and we are now looking forward to obtain the results from the high-dose group. Moreover, this is the first time for a second generation virosome-based vaccine that we verified the generation of memory in humans by means of a booster immunization."

The follow-up of the group of volunteers vaccinated with the intramuscular high dose of PEV7 is ongoing and so far has shown high and persistent antibody titers until six months after completion of the vaccination course. In order to evaluate the intravaginal application of PEV7 in capsule form, an additional study arm is ongoing.
'/>"/>

SOURCE Pevion Biotech AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Stemline Therapeutics, Inc. Names Eric K. Rowinsky, M.D. Chief Medical Officer and Head of Research and Development
2. Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics
3. Silence Therapeutics Signs Collaboration with miRagen Therapeutics to Evaluate Delivery of Novel microRNA-based Therapeutics
4. Lightlake Therapeutics Inc. to Apply Companys Patented Technology in the Development of Premenstrual Syndrome Overeating Treatment
5. Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003
6. Orexigen Therapeutics to Present at the J.P. Morgan Healthcare Conference
7. Halo Therapeutics HT-100 Receives FDAs Orphan Designation for Duchenne Muscular Dystrophy
8. Echo Therapeutics Announces $3.6 Million Warrant Exercises
9. Echo Therapeutics to Present at Biotech Showcase 2012 in San Francisco
10. Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock
11. AuraSense Therapeutics Secures Series B Equity Investment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 Levi & Korsinsky announces it ... OHRP ) concerning possible violations of federal securities ... Company in connection with its study of the drug ... or contact Joseph E. Levi, Esq. ... telephone at (212) 363-7500, toll-free: (877) 363-5972. ...
(Date:3/27/2015)... MONTREAL , March 27, 2015 /CNW Telbec/ - ... Research-Based Pharmaceutical Companies (Rx&D), welcomes the 2015-2016 ... of a working group on the biopharmaceutical industry. However, ... medicines budget. "We commend the government,s intent ... the announcement of measures to promote Quebec,s ...
(Date:3/27/2015)... The Temple Health & Bioscience District (THBD) today announced it ... South First St. in the Temple Medical and Education District ... of Temple to receive funding for redevelopment. Located ... Health Care System, the new facility will enable THBD to ... life science companies. Temple ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2
... 2011 Samplify Systems, Inc., a leading provider of ... scientific markets, has completed its Series B round of ... fund its rapid growth in its existing markets, and ... the round are Integrated Device Technology, Inc. (Nasdaq: ...
... THOUSAND OAKS, Calif., March 4, 2011 Amgen (Nasdaq: ... the acquisition of BioVex Group, Inc., a privately held ... in Abingdon, UK. The acquisition includes OncoVEX(GM-CSF), a novel ... may represent a new approach to treating melanoma and ...
Cached Medicine Technology:Samplify Systems Completes Series B Funding 2Samplify Systems Completes Series B Funding 3Amgen Completes Acquisition of BioVex 2Amgen Completes Acquisition of BioVex 3Amgen Completes Acquisition of BioVex 4
(Date:3/28/2015)... 28, 2015 Andrew Hawley of Vintage Rock ... psychedelic concert posters. The Who and the Doors played together ... 2, 1968. According to Hawley, “The Who toured the United ... and college campuses. Perhaps the most famous Who poster was ... and the Doors on August 2, 1968 at the Singer ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Association Annual Conference to be held April 10-11, ... Columbus, OH. , The OPTA Annual Conference ... products and services. , Representatives from Aureus ...
(Date:3/28/2015)... 2015 The "Petrick Sustainable Health ... health. After 18 years of research and experience with ... contenders, Dr. Jon Petrick is excited to be launching ... of the immediate benefits of this radical new system ... of strength of the immune system, faster healing of ...
(Date:3/28/2015)... March 28, 2015 ARDX will sponsor the ... 12pm -3pm at the Chesapeake Conference Center in Chesapeake, Virginia. ... an empowering event for women in the Hampton Roads region. ... Stories of Women’s Lives. Women grow stronger through sharing ... other. This year the WWC™ theme is T-talk where ...
(Date:3/28/2015)... 28, 2015 Servpro of Paso ... week released a report about the link between mold ... sufferers, and according to recent medical research, may even ... to the Environmental Protection Agency, people with sensitivity to ... in mold may trigger asthma attacks for asthma sufferers. ...
Breaking Medicine News(10 mins):Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3
... peers are doing seems to matter, expert surmise, , MONDAY, ... friends really weren,t drinking as much as it might seem, ... , Researchers from Oxford Brookes University in England reviewed 22 ... States. The researchers divided the students into two groups: those ...
... NASHVILLE, Tenn., July 20 HealthLeaders-InterStudy, a leading ... the Los Angeles market are struggling to recruit physicians, particularly ... the recent Los Angeles Market Overview , ... to physicians, ranging from $250 to $4,000 a day, to ...
... , PITTSBURGH, July 20 Mylan Inc. (Nasdaq: ... million preferred stock issuance, the company has declared its quarterly dividend of ... a liquidation preference of $1,000.00 per share) payable on August 17, 2009, ... , , Mylan Inc., which provides products ...
... , SEATTLE, July 20 Group Health ... 15 quality measures in the Puget Sound Health Alliance Community ... any of the other nine medical groups in the Puget Sound region ... Health received no "below regional average" scores. , , ...
... , , CLEVELAND, July 20 ... global eClinical solutions for the clinical trials industry, announced today that ... DATATRAK CRO Connect Program(TM). ARA will utilize DATATRAK eClinical(TM) to ... paper and EDC clients. , , ...
... , , ... 20 Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ) today announced that ... drug for the treatment of obesity, met their co-primary endpoints. The results ... besity R esearch, or COR, program of more than 4,500 ...
Cached Medicine News:Health News:Perception May Affect Drinking by College Students 2Health News:l.a. Hospitals Struggle for Emergency Room Care, Pay Physicians High Fees for On-Call Coverage 2Health News:Group Health Cooperative Scored Above Regional Average in 11 of 15 Quality Measures 2Health News:Advance Research Associates Joins DATATRAK's CRO Connect Program(TM) 2Health News:Advance Research Associates Joins DATATRAK's CRO Connect Program(TM) 3Health News:Advance Research Associates Joins DATATRAK's CRO Connect Program(TM) 4Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 2Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 3Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 4Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 5Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 6Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 7Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 8Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 9
... ,The S/5 Critical Care Monitor is a multiparameter ... varying needs of critical care. The S/5 Critical ... options, display and mounting options, remote control and ... set-up to help meet your needs. The new ...
... for size., ,The Datex-Ohmeda S/5 Light Monitor ... in anesthesia and critical care areas, in emergency ... transport. As part of the Datex-Ohmeda S/5 family, ... user interface and design shared by all S/5 ...
... to use., ,The S/5 Compact Critical ... ideally suited for medium care monitoring. The ... Datex-Ohmeda supplies and accessories., ,The S/5 ... user interface and features as the S/5 ...
... need in day surgery and post anesthesia care ... Anesthesia Monitor is a high performance monitor designed ... anesthesia care and induction rooms. It offers the ... parameters and advanced airway gas monitoring. When paired ...
Medicine Products: